Earnings
Perimeter Announces Preliminary Unaudited Fourth Quarter and Full Year 2025 Financial Results Marked by Record Revenues and Improved Operating Performance
Perimeter Clears FDA Hurdle and Posts Record Sales, But Cash Runway and Dilution Threaten Near-Term Upside
Executive Summary
- Perimeter released preliminary unaudited Q4 and full-year 2025 financial results on March 31, 2026.
- Q4 2025 revenue reached ~$711,000 (up 143% YoY, up 33% sequentially), driving full-year 2025 revenue to ~$2.3 million (up 172% YoY).
- Operating expenses declined 46% YoY in Q4 and 26% YoY for the full year, narrowing the FY2025 net loss to ~$12.9 million from $13.4 million in 2024.
- Cash used in operating activities improved 36% YoY to ~$9.3 million, leaving a cash balance of ~$2.5 million as of December 31, 2025.
- The company confirmed FDA Premarket Approval (PMA) for Claire, its AI-enabled intra-operative breast cancer margin assessment device, with a U.S. commercial launch planned for Q2 2026.
- Management highlighted continued S-Series OCT system adoption, including deployments at HCA HealthONE Rose and a systemwide agreement with Intermountain Health.
- Corporate actions included a December 2025 non-brokered private placement of 19.76 million units at C$0.18, a February 2026 employee option repricing (cancelling C$0.38–C$2.85 options and re-issuing at C$0.30), and a March 2026 warrant cancellation agreement with Social Capital surrendering 14.47 million warrants for no consideration.
Material Impact
- The financial results validate the company's commercial inflection point, but the revenue base remains small relative to the $12.9 million annual net loss.
- The FDA PMA for Claire was already announced on March 3, 2026. The March 31 release serves as a financial confirmation rather than a new catalyst.
- The Social Capital warrant cancellation removes a significant near-term overhang (~14.5 million shares), which is structurally positive for existing shareholders and reduces potential dilution pressure.
- The most critical takeaway is the cash position. With only $2.5 million on hand and an annual operating cash burn of ~$9.3 million, the company faces an immediate liquidity shortfall. This necessitates near-term capital raising, which will likely be dilutive.
- Management's option repricing signals potential retention challenges or an attempt to align incentives with a depressed stock price, but it also increases future share count dilution.
- Overall, the news confirms operational progress and removes warrant overhang, but the severe funding gap and unaudited nature of the results temper enthusiasm.
PINK · Price
Company Overview
- Perimeter Medical Imaging AI develops optical coherence tomography (OCT) imaging systems for intra-operative tissue visualization.
- Flagship Project 1: S-Series OCT system, FDA 510(k) cleared for general tissue imaging, currently deployed in select U.S. hospitals (e.g., HCA HealthONE Rose, Intermountain Health).
- Flagship Project 2: Claire, an AI-enabled OCT device specifically for intra-operative breast cancer margin assessment. Received FDA PMA in March 2026, targeting ~300,000 annual U.S. breast-conserving surgeries.
- Pipeline: B-Series OCT system integrating AI (ImgAssist), currently under FDA substantive review with a decision expected in H1 2026.
More from Perimeter Medical Imaging AI, Inc.
Jun 09, 2026 · 09:05